Gossamer Bio to Report Q4 2025 Earnings on Thursday

Analysts expect the biotech company to post a loss of $0.19 per share and revenue of $7.52 million.

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Gossamer Bio (NASDAQ:GOSS) is scheduled to release its fourth quarter 2025 financial results before the market opens on Thursday, March 12, 2026. The clinical-stage biopharmaceutical company focused on immune-mediated and inflammatory diseases is expected to report a loss of $0.19 per share on revenue of $7.52 million for the quarter.

Why it matters

Gossamer Bio's earnings report will provide investors with an update on the company's financial performance and the progress of its drug development pipeline, which includes lead programs GB004 for ulcerative colitis and GB1275 for solid tumors and hematologic malignancies.

The details

Gossamer Bio will hold a conference call to discuss the Q4 2025 results on Wednesday, March 11, 2026 at 4:00 PM ET. Analysts will be looking for details on the company's clinical trials, regulatory filings, and overall business strategy.

  • Gossamer Bio will release its Q4 2025 earnings before the market opens on Thursday, March 12, 2026.
  • The company will hold a conference call to discuss the results on Wednesday, March 11, 2026 at 4:00 PM ET.

The players

Gossamer Bio

A clinical-stage biopharmaceutical company headquartered in San Diego, California that is focused on developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications.

Got photos? Submit your photos here. ›

What’s next

Investors will be watching for updates on Gossamer Bio's lead drug candidates GB004 and GB1275, as well as any guidance the company provides on its financial outlook and clinical development timelines.

The takeaway

Gossamer Bio's Q4 2025 earnings report will be an important milestone for the company as it continues to advance its pipeline of novel therapies for difficult-to-treat conditions. The results and management commentary will provide insight into the company's progress and future prospects.